161 related articles for article (PubMed ID: 38506974)
21. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
Perez-Ruixo C; Ackaert O; Ouellet D; Chien C; Uemura H; Olmos D; Mainwaring P; Lee JY; Yu MK; Perez-Ruixo JJ; Smith MR; Small EJ
Clin Cancer Res; 2020 Sep; 26(17):4460-4467. PubMed ID: 32561663
[TBL] [Abstract][Full Text] [Related]
23. Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
Pan A; Reingold RE; Zhao JL; Moy A; Kraehenbuehl L; Dranitsaris G; McBride SM; Scher HI; Kollmeier MA; Xiao H; Rathkopf DE; Lacouture ME
J Urol; 2022 May; 207(5):1010-1019. PubMed ID: 35020444
[TBL] [Abstract][Full Text] [Related]
24. Apalutamide and Overall Survival in Prostate Cancer.
Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; De Porre P; Smith AA; Brookman-May SD; Li S; Zhang K; Rooney B; Lopez-Gitlitz A; Small EJ
Eur Urol; 2021 Jan; 79(1):150-158. PubMed ID: 32907777
[TBL] [Abstract][Full Text] [Related]
25. Apalutamide for the treatment of patients with castration-resistant prostate cancer.
Hauke R
Drugs Today (Barc); 2018 Oct; 54(10):585-590. PubMed ID: 30398479
[TBL] [Abstract][Full Text] [Related]
26. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
Feng FY; Thomas S; Saad F; Gormley M; Yu MK; Ricci DS; Rooney B; Brookman-May S; McCarthy S; Olmos D; Chowdhury S; Hadaschik B; Liu Y; Davicioni E; Smith MR; Small EJ
JAMA Oncol; 2021 Jul; 7(7):1005-1014. PubMed ID: 34081076
[TBL] [Abstract][Full Text] [Related]
27. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
Werutsky G; Maluf FC; Cronemberger EH; Carrera Souza V; Dos Santos Martins SP; Peixoto F; Smaletz O; Schutz F; Herchenhorn D; Santos T; Mavignier Carcano F; Queiroz Muniz D; Nunes Filho PRS; Zaffaroni F; Barrios C; Fay A
BMC Cancer; 2019 May; 19(1):487. PubMed ID: 31122212
[TBL] [Abstract][Full Text] [Related]
28. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
[TBL] [Abstract][Full Text] [Related]
29. [Apalutamide, Erleada®].
Sautois B; Denis C
Rev Med Liege; 2022 Oct; 77(10):609-615. PubMed ID: 36226398
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Uemura H; Arai G; Uemura H; Suzuki H; Aoyama J; Hatayama T; Ito M; Lefresne F; McCarthy S; Mundle S; He J; Chi KN
Int J Urol; 2022 Jun; 29(6):533-540. PubMed ID: 35293030
[TBL] [Abstract][Full Text] [Related]
31. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Oudard S; Hadaschik B; Saad F; Cella D; Basch E; Graff JN; Uemura H; Dibaj S; Li S; Brookman-May SD; De Porre P; Bevans KB; Trudeau JJ; Small EJ; Smith MR
Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Rathkopf DE; Smith MR; Ryan CJ; Berry WR; Shore ND; Liu G; Higano CS; Alumkal JJ; Hauke R; Tutrone RF; Saleh M; Chow Maneval E; Thomas S; Ricci DS; Yu MK; de Boer CJ; Trinh A; Kheoh T; Bandekar R; Scher HI; Antonarakis ES
Ann Oncol; 2017 Sep; 28(9):2264-2271. PubMed ID: 28633425
[TBL] [Abstract][Full Text] [Related]
33. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
[TBL] [Abstract][Full Text] [Related]
34. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
35. Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.
Lowentritt B; Pilon D; Khilfeh I; Rossi C; Muser E; Kinkead F; Waters D; Ellis L; Lefebvre P; Brown G
Urol Oncol; 2023 May; 41(5):253.e1-253.e9. PubMed ID: 37061452
[TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects.
Pérez-Ruixo C; Pérez-Blanco JS; Chien C; Yu M; Ouellet D; Pérez-Ruixo JJ; Ackaert O
Clin Pharmacokinet; 2020 Feb; 59(2):229-244. PubMed ID: 31432469
[TBL] [Abstract][Full Text] [Related]
37. Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study.
Oishi T; Hatakeyama S; Tabata R; Fujimori D; Kawashima Y; Tanaka R; Ishii N; Miura H; Tanaka T; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Sato S; Ohyama C
Prostate; 2023 Feb; 83(2):198-203. PubMed ID: 36314250
[TBL] [Abstract][Full Text] [Related]
38. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
[TBL] [Abstract][Full Text] [Related]
39. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer.
Belderbos BPSI; de Wit R; Chien C; Mitselos A; Hellemans P; Jiao J; Yu MK; Attard G; Bulat I; Edenfield WJ; Saad F
Cancer Chemother Pharmacol; 2018 Sep; 82(3):457-468. PubMed ID: 29974203
[TBL] [Abstract][Full Text] [Related]
40. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
Smith MR; Thomas S; Gormley M; Chowdhury S; Olmos D; Oudard S; Feng FY; Rajpurohit Y; Urtishak K; Ricci DS; Rooney B; Lopez-Gitlitz A; Yu M; Wyatt AW; Li M; Attard G; Small EJ
Clin Cancer Res; 2021 Aug; 27(16):4539-4548. PubMed ID: 34112710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]